Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension (RSD4CKD)
Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Anticipado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Shan Qi Jun, Professor
- Número de teléfono: 0086 025 68136407
- Correo electrónico: qjshan@njmu.edu.cn
Ubicaciones de estudio
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210000
- Reclutamiento
- First Affiliated Hospital of Nanjing Medical University
-
Contacto:
- Shan Qi Jun, Professor
- Número de teléfono: 0086 025 68136407
- Correo electrónico: qjshan@njmu.edu.cn
-
Investigador principal:
- Shan Qi Jun, Professor
-
Investigador principal:
- Xing Ch Ying, Professor
-
Investigador principal:
- Chen Chun, Professor
-
Sub-Investigador:
- Zhou X Juan, Professor
-
Sub-Investigador:
- Qian W Chong, Professor
-
Sub-Investigador:
- Liu Jia, Professor
-
Sub-Investigador:
- Yu X Bao, Professor
-
Sub-Investigador:
- Mao H Juan, Professor
-
Sub-Investigador:
- Yao Jing, Doctor
-
Sub-Investigador:
- Xu X Qiang, Doctor
-
Sub-Investigador:
- Wang X Mei, Nurse
-
Sub-Investigador:
- Duan X Yan, Master
-
Sub-Investigador:
- Qiu Min, Master
-
Sub-Investigador:
- Geng Jie, Master
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Subject is ≥ 18 and ≤75 years of age.
- A serum creatinine level of 1.5 to 5.0 mg per deciliter (133 to 442 μmol per liter), a creatinine clearance of 20 to 70 ml per minute per 1.73 m2, with variations of less than 30 percent in the three months before randomization.
- Persistent proteinuria (defined by urinary protein excretion of more than 0.3 g per day for three or more months which can evacuate urinary tract infection and overt heart failure [a New York Heart Association class of III or IV]).
- Resistant hypertension.
- Nondiabetic renal disease.
- Subject is willing and able to comply with the protocol
- Subject is expected to remain available for follow-up visits at the study center
- Subject Informed Consent.
Exclusion Criteria:
- Current treatment with corticosteroids, nonsteroidal antiinflammatory drugs, or immunosuppressive drugs.
- Connective-tissue disease.
- Obstructive uropathy.
- Congestive heart failure (New York Heart Association class III or IV).
- Subject has significant renovascular abnormalities (a history of prior renal artery intervention, including balloon angioplasty or stenting; double renal artery on one side, distortion, and extension ), measured by abdominal ultrasound or renal angiograms.
- Subject has a history of myocardial infarction, unstable angina, cerebrovascular accident or alimentary tract hemorrhage in the previous 3 months.
- Subject with sick sinus syndrome.
- Subject has a history of allergy to contrast media; psychiatric disorders; drug or alcohol abuse; and pregnancy.
- Enrolled in a concurrent study that may confound the results of this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: RSD+Medicine
The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria.
First undergo renal artery angiography procedure to confirm anatomy.
If renal artery meet the inclusion criteria, give the renal sympathetic denervation.
At the same time, we will use optimal medication to protect renal function.
Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
|
Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD.
Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery.
then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
About six to nine ablations at 10 W for 1 min each were performed in both renal arteries.
During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
Otros nombres:
|
|
Comparador de placebos: Medicine
The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria.
There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups.
In this group we will use optimal medication just like the RSD+Medicine group.
Third we will conduct a clinic and a telephone follow-up(Total 36 months).
|
Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
All-cause mortality, doubling of the serum creatinine level or end-stage renal disease
Periodo de tiempo: 36 months
|
To study the effect of renal sympathetic denervation(RSD) on all-cause mortality,doubling of the serum creatinine level or end-stage renal disease in patients with chronic kidney disease and resistant hypertension.
|
36 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Urinary protein excretion and renal function
Periodo de tiempo: 36 months
|
To evaluation of urinary protein excretion and renal function over time, by the reciprocal of the serum and urinary creatinine level, creatinine clearance and the glomerular filtration rate.
|
36 months
|
|
Blood pressure
Periodo de tiempo: 36 months
|
To study the effect of renal sympathetic denervation on blood pressure in patients with hypertension, which can be measured by ambulatory blood pressure and home blood pressure monitoring.
|
36 months
|
|
Blood sugar
Periodo de tiempo: 36 months
|
In order to study whether RSD can reduce the blood sugar level and insulin resistance of diabetic patients.
It will be measured by fasting blood glucose, glycated hemoglobin, fasting insulin .
|
36 months
|
|
Cardiac function and structure
Periodo de tiempo: 36 months
|
The effect of renal sympathetic denervation(RSD) on cardiac function and structure can be measured by echocardiographic(include the degree of cardiac pachynesis, left ventricular ejection fraction,left ventricular end diastolic diameter, ventricular septal thickness and so on).
|
36 months
|
|
Arrhythmia
Periodo de tiempo: 36 months
|
If a new arrhythmia is discovered during the follow-up, it will be recorded.
Patients may have symptoms of flustered, palpitations, dizziness, amaurosis, syncope and so on, which can be diagnosed by ECG and Holter.
|
36 months
|
|
Pulse wave velocity
Periodo de tiempo: 36 months
|
So as to study whether RSD can improve the patients' blood vessel elasticity, a pulse wave velocity (PWV)will be carried on.
|
36 months
|
|
Life quality
Periodo de tiempo: 36 months
|
Life quality on 36-item short-form(SF-36),HRQoL and PRODISQ Health Survey Questionnaire will be carried out during the follow-up to study the patients' life quality.
|
36 months
|
|
Rehospitalization rate
Periodo de tiempo: 36 months
|
To study whether RSD can reduce the patients' rehospitalization rate, which will be measured by questionnaire and telephone follow-ups.
|
36 months
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dialysis
Periodo de tiempo: 36 months
|
In order to study the effect of renal sympathetic denervation on renal function in patients with dialysis, which can be measured by the proportion of patients who do not need dialysis anymore.
|
36 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Shan Qi Jun, professor, The First Affiliated Hospital with Nanjing Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización primaria
Finalización del estudio (Anticipado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2012-SR-142
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .